Norge - norsk - Statens legemiddelverk

boehringer ingelheim animal health nordics - borrelia garinii / borrelia afzelii / borrelia burgdorferi sensu stricto - injeksjonsvæske, suspensjon

Norge - norsk - Statens legemiddelverk

boehringer ingelheim animal health nordics - valpesykevirus, inaktivert / hundeparvovirus, stamme cornell cag2, levende / hundeadenovirus 2, stamme dk13, levende / hundeparainfluensa 2, stamme cgf 2004/75, levende - lyofilisat og væske til injeksjonsvæske, suspensjon

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katter - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immunitetstrinn har blitt vist en uke etter primær vaksinasjonskurs for rhinotrakeitt, calicivirus, chlamydophila felis og panleukopeni-komponenter. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - feline leukemi virus rekombinant canarypox virus (vcp97) - immunologicals for felidae, - katter - aktiv immunisering av katter på 8 uker eller eldre mot feline leukemi for forebygging av vedvarende viraemi og kliniske tegn på den relaterte sykdommen. immunitetsbegyndelsen har blitt påvist 2 uker etter primær vaksinering. varighet av immunitet er ett år etter siste vaksinasjon.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - rekombinant tyrkia herpes-virus, belastning vhvt013-69, live - immunologicals for aves, innenlandske fugler, immunologicals - embryonated eggs; chicken - for aktive vaksinering av kyllinger:for Å forhindre dødelighet og for å redusere kliniske tegn og lesjoner av smittsom sykdom bursal. for å redusere dødelighet, kliniske tegn og lesjoner av marek ' s sykdom.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - vcp 2242 virus / vcp1529 virus / vcp1533 virus / vcp3011 virus - immunologicals, live viral vaksiner equine influenza virus - hester - aktiv immunisering av hester av fire måneder eller eldre mot hesteinfluensa for å redusere kliniske tegn og virusutskillelse etter infeksjon.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - clostridium tetani toxoid / vcp 2242 virus / vcp1529 virus / vcp1533 virus / vcp3011 virus - immunologicals for equidae, live viral and inactivated bacterial vaccines, equine influenza virus + clostridium - hester - aktiv immunisering av hester på fire måneder eller eldre mot hesteinfluensa for å redusere kliniske tegn og virusutskillelse etter infeksjon, og mot tetanus for å forhindre dødelighet.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - katter - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.